CERO Company Profile and Key Details

The stock is currently trading near its 52-week low $0.03 and $28.40. With a market capitalization of about $39.90 thousand, CERo Therapeutics Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.32). Key stats such as the average daily volume over the past year has been around 519.89 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, CERo Therapeutics Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher Ehrlich, the company employs approximately 8 people and listed since November 30, 2021. CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.

CERO has shown weak momentum, losing -95.24% over the past week and -98.76% over the past quarter, though year-to-date performance is down -99.92%. Short-term trend indicators are bullishly aligned (SMA20 -96.73%, SMA50 -98.04%, SMA200 -99.37%). The stock’s 14-day RSI is 12.27 (weak momentum), while the ATR of 0.44 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.99% below its high and over 11.88% above its low. Average 10-day trading volume of 207.19 thousand shares is below the 3-month average of 516.99 thousand, indicating normal recent market interest.

CERo Therapeutics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.45. This means the shares are trading below this model’s fair value.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $30.00. The high target offers 99900.0% upside. The low target suggests 99900.0% downside. The mean target is $30.00. This offers 99900.0% upside. CERo Therapeutics Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended November 19, 2025, missed forecasts by 1097.37%. The prior quarter beat by -50.34%. Over the last six quarters, Apple has recorded several small beats. These include -73.32% in May 15, 2025.

CERo Therapeutics Holdings, Inc. has 1.21 million shares outstanding. The public float is 1.10 million shares, elevated short interest at 3.23% of float. This equals 38.01 thousand shares. The short ratio is 1.0 days. Institutional investors hold 26.68% of the float. Insiders own 3.55%.